Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development

NCT00420251 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT00420251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00420251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Phase 3
Overall status
Completed
Start date
March 31, 1996
Completion date
July 31, 2006
Enrollment
50
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis, still disease, juvenile-onset